George I. Salti, MD
Dr. George I. Salti is a surgical oncologist with Endeavor Health in Illinois. He is known for his expertise in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal or abdominal cancers. The procedure is life-changing for many patients with peritoneal mesothelioma.[1]
Education and Career
Dr. Salti earned his medical degree at the University of Chicago Pritzker School of Medicine. He completed his internship and residency in General Surgery at the University of Illinois at Chicago and the University of Illinois Hospital.
He completed a Surgical Oncology fellowship at the University of Illinois, Department of Surgery. He is board-certified by the American Board of Surgery.
Dr. Salti is currently a surgical oncologist with Endeavor Health, where he sees patients in Naperville and Elmhurst, Illinois. He also sees patients through UI Health at the Outpatient Care Center in Chicago.[2]
Dr. Salti is recognized as a pioneer in the treatment of peritoneal mesothelioma and other complex abdominal cancers with HIPEC and cytoreductive surgery. He was the first surgeon in the Chicago area to perform the treatment in the early 2000s. Dr. Salti has also performed the innovative PIPAC procedure (pressurized intraperitoneal aerosol chemotherapy).
Professional Memberships and Activities
Dr. Salti is an active member of several professional medical societies and associations, including:[1]
• American College of Surgeons
• American Society of Clinical Oncology
• American Society of Peritoneal Surface Malignancy
• Society of Melanoma Research
• Society for American Gastrointestinal Endoscopic Surgeons
• Society of Surgical Oncology
Research
Dr. Salti is actively involved in clinical trials investigating the outcomes of cytoreductive surgery and HIPEC in community settings, as well as in tracking patients following those procedures via the University of Illinois HIPEC clinical data registry.
Selected Publications:[1]
• Naffouje SA, O’Donoghue C, Salti GI. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital’s initial experience and reflections on the health care system. J Surg Oncol. 2016 Jan 11.
• Naffouje S, Naffouje R, Bhagwandin S, Salti GI. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival. Melanoma Res. 2015 Dec;25(6):496-502.
• Bhagwandin SB, Salti GI.Tumori. Hepatocellular carcinoma with peritoneal metastasis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. 2015 Mar 20;101(1):e1-3.
• Bhagwandin S, Naffouje S, Salti G. Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2015 Aug;22(8):2573-7.
• Bhagwandin SB, Naffouje S, Salti G. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge. J Surg Oncol. 2014 Dec 31.
• Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014 Dec;110(7):779-85.
